Trial Profile
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications Cognition disorders; HIV infections
- Focus Proof of concept; Therapeutic Use
- 20 Feb 2016 Results published in the AIDS
- 10 Feb 2016 New trial record